Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: J Nutr Biochem. 2022 Mar 26;105:108998. doi: 10.1016/j.jnutbio.2022.108998

Fig. 4. Piceatannol administration suppresses fasting-induced serum glycerol and obesity-associated central adiposity in vivo.

Fig. 4.

Overnight fasted wild-type obese C57BL/6J mice (n=3/group) were subjected to i.p. injection of piceatannol (10 mg/kg body weight) or vehicle solution for 8 h followed by serum glucose (A) and glycerol (B) analyses. Diet-induced obese mice (n=6–8/group) were administered (10 mg/kg body weight) via i.p. injection for 15 days. Body weight (C) and food intake (D) were measured during the study. Weight of liver and WAT (Epi: epididymal, Ing: inguinal, Ret: retroperitoneal) (E) and percent fat mas and lean mass (F) were measured at the end of the study. After 14-days of piceatannol administration, mice were put into a metabolic chamber to measure energy expenditure (EE) (G) and respiratory exchange ratio (RER) (H). Data are presented as means ± SEM. (*, p < 0.05).